ClinicalTrials.gg
CompletedNCT00224406Updated Dec 11, 2024Results posted

Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation

A Phase 2 interventional study of Repertaxin and Placebo in Ischemia-Reperfusion Injury and Lung Transplantation, sponsored by Dompé Farmaceutici S.p.A. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by Dompé Farmaceutici S.p.A · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2005, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 44 studies in Reperfusion Injury with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Reperfusion Injury · United States.

Enrollment
7th of 39
114 · median 30
Started
2005
with 1 other
Phase 2
11 of 44
none open now
Registered
4th of 44
by date
Lead sponsor
2 of 44
Dompé Farmaceutici S.p.A

Among the 44 studies in Reperfusion Injury with a site in United States, this one is the 7th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2005, is one of 11 in phase 2, and was the 4th registered.

Reperfusion Injury

260 studies on the registry are indexed under Reperfusion Injury; 43 are open to participants now.

Browse Reperfusion Injury studies →

Open to participants now

5 of the 44 studies in Reperfusion Injury with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Reperfusion Injury studies recruiting now, 16 (57%) set no upper age limit and 7 (25%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Reperfusion Injury with a site in United States, or all of them as a file.
02

Study summary

The objective of this clinical study was to evaluate whether CXCL8 (CXC ligand 8 [formerly interleukin (IL)-8]) inhibition with repertaxin leads to reduced severity of primary graft dysfunction, as the result of improved functional and clinical outcomes in lung transplantation patients.

The safety of repertaxin in the specific clinical setting was also evaluated.

The ability of repertaxin to reduce target cells (polymorphonuclear leukocyte [PMN]) infiltration into the graft was evaluated to confirm its mechanism of action.

Read the detailed description

This was a phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel-group (two arms) study.

A total of 100 patients accepted and listed for lung transplantation, who met all of the study inclusion and none of the exclusion criteria described in Sections 9.3.1 and 9.3.2 of this report, were planned to be enrolled in the study. These patients were randomly assigned in a 1:1 ratio to receive either repertaxin or placebo, by continuous intravenous infusion for a period of 48 hours to start approximately 2 hours before reperfusion of the (first) transplanted lung occurred.

The experimental treatment was additional to the standard treatment of lung transplant recipients.

An initial 'loading dose' of repertaxin of 4.488 mg/kg body weight/hour was to be administered over 30 minutes followed by a maintenance dose of 2.772 mg/kg body weight/hour lasting 47.5 hours.

Placebo was to be volume matched saline. Total infusion volume was not to exceed 500 mL/24 hours. Study medication was to be provided as clear glass class I ampoules, each containing 10 mL of the following products: repertaxin (33 mg/mL aqueous injectable solution) and placebo (9 mg/mL aqueous injectable solution of NaCl).

The double-blind was to be maintained for the main part of the study only, i.e. up to the Month 1 (at least 30 days post-transplant) follow-up visit of the last patient in. After database lock of Month 1 data the study proceeded in an open fashion.

03

Conditions studied

  • Ischemia-Reperfusion Injury
  • Lung Transplantation

Browse trials for

Keywords

  • Lung transplantation
  • Reperfusion Injury
  • Survival
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients accepted and listed for transplantation due to irreversible, progressive disabling, end-stage pulmonary disease;
  • Ages 18 to 65 years;
  • Body weight 30 to 95 kg (inclusive) (i.e. up to 95.99 kg);
  • Planned isolated (single and bi-lateral) lung transplant from a non-living donor with brain death. This included lobar lung transplant involving excision and sizing of a cadaver donor lobe to meet the thoracic dimension of the recipient before being transplanted;
  • Normal renal function at the time of transplant as per calculated (Clcr) 60 mL/min. Creatinine clearance was calculated according to the Cockcroft-Gault formula;
  • Patient was willing and able to comply with the protocol procedures for the duration of the study, including scheduled follow-up visits and examinations;
  • Patient gave written , prior to any study-related procedure not part of normal medical care, with the understanding that consent could be withdrawn by the patient at any time without prejudice to their future medical care.

Exclusion criteria

Exclusion Criteria:

  • Recipients of an intended multiple organ transplant, including heart-lung and liver-lung transplantation;
  • Recipients of a lung from a living lobar donor;
  • Recipients of a lung from a non-heart beating donor;
  • Re-do lung transplantation;
  • Recipients requiring mechanical ventilation at the time of transplant;
  • Recipients with an extra-respiratory tract site of infection (positive blood culture(s) and/or fever associated with other signs of systemic sepsis syndrome). The criterion was not meant to exclude bacteraemic cystic fibrosis patients with or without fever, unless they presented with other signs of sepsis;
  • Recipients with hepatic dysfunction ( exceeding 3 mg/dL and/or transaminases >3X [ULN]) at the time of transplant;
  • to:

    • Ibuprofen or to more than one non steroidal anti-inflammatory drug (NSAID);
    • Medications belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib;
  • Patients simultaneously participating in any other studies involving a study drug to be administered concomitantly with the product and/or a study drug intended to prevent ischemia/reperfusion injury;
  • Planned use of anli-CD3 monoclonal antibody (Orthoclone OKT3) or alemtuzumab (Campath) induction ;
  • Planned use of sirolimus in the first 3 months after transplantation;
  • Pregnant or breast-feeding women (NB: pregnancy was lo be avoided in patients or partners during the first month of participation in the study; no other specific warnings were described, considering even stricter general recommendations concerning pregnancy in transplanted patients, the treatment course of the investigational product, its pharmacokinetic profile, and the lack of significant adverse effects on mating performance and fertility in animal studies).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Repertaxin

    Both repertaxin and placebo were aqueous solutions packaged into identical clear glass Type I ampoule single dose units. Each ampoule contained 10 mL of either repertaxin or placebo.The dosing solution for infusion was prepared aseptically at the designated Pharmacy within each center and dispensed as 12.65 mg/mL solution in appropriate size infusion bags. An initial 'loading dose' of Repertaxin of 4.488 mg/kg body weight/hour was administered over 30 minutes followed by a maintenance dose of 2.772 mg/kg body weight/hour lasting 47.5 hours.The loading and maintenance doses were administered using the same dosing solution (Repertaxin 12.65 mg/ml), but with the pump rate altered to provide an infusion rate of approximately 0.35 mUkg/hour and 0.22 ml/kg/hour, respectively.

    Drug: Repertaxin

  • Placebo comparator
    Placebo

    Both repertaxin and placebo were aqueous solutions packaged into identical clear glass Type I ampoule single dose units. The dosing solution for infusion was prepared aseptically at the designated Pharmacy within each center and dispensed as 12.65 mg/mL solution in appropriate size infusion bags. ampoule contained 10 mL of either repertaxin or placebo. An initial 'loading dose' of 9 mg/ml sodium chloride (NaCl) solution was administered over 30 minutes, followed by a maintenance dose lasting 47.5 hours.

    Other: Placebo

Interventions

  • DrugReparixinStudies of ReparixinReparixin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    An initial 'loading dose' of repertaxin was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The study medication was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.

  • OtherPlacebo

    An initial 'loading dose' of placebo was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The placebo was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.

    Also known as: Placebo comparator

06

What researchers measure

Primary outcomes

  1. PaO2/FiO2 Ratio at ICU Admission (Time 0) and 24 Hours

    The PaO2/FiO2 ratio was calculated to assess the severity of hypoxemia, or low blood oxygen levels. A low PaO2/FiO2 value has been associated with increased mortality and hospital stay in patients admitted to the intensive care unit (ICU). It was calculated by dividing the partial pressure of oxygen in arterial blood (PaO2) by the fraction of inspired oxygen (FiO2). A normal P/F ratio was typically above 300, and a lower ratio indicates a greater severity of hypoxemia. As the Pa02/Fi02 ratio was dependent on altitude, data were corrected for altitude in the analyses of corrected data. The correction factor is defined as (Pressure at Denver)/(Pressure at sea level) = 633/760 = 0.8329; PaO2 values were corrected as follows: Corrected value = measured value/0.8329

    Time frame: At T0 (time of ICU admission) and 24 hours post-ICU admission

Secondary outcomes

  1. PaO2/FiO2 Ratio (ICU Admission Then 24 Hours up to Extubation or up to 72 Hours)

    Time profile of oxygenation was a comparison of the sequential measurements of the ratios of arterial PaO2 to inspired oxygen fractions FiO2. Herein repeated measurements analysis of PaO2/FiO2 ratio corrected after ICU admission using a one-sided test excluding missing data.

    Time frame: At ICU admission (T0), 24, 48 and 72 hours post-ICU admission

  2. Number of Patients With Different Primary Graft Dysfunction (PGD) Scores (0-3, and Missing Data)

    PGD after lung transplantation ranged from mild to severe depending on the level of hypoxaemia and lung injury post-transplant. PGD score was calculated according to the scoring system below: Grade 0 PaO2/FiO2 \>=300 mmHg; no radiographic infiltrates (RI); Grade 1 PaO2/FiO2 \>=300mmHg + RI consistent with pulmonary oedema; Grade 2 200 mmHg \<=PaO2/FiO2 \<=300 mm Hg + RI consistent with pulmonary oedema; Grade 3 PaO2/FiO2 \< 200 mm Hg + RI consistent with pulmonary oedema. The higher the score, the worse the outcome. Any patient with no infiltrate on chest X-rays was automatically Grade 0. If the patient was on nasal cannula for oxygen or FiO2 \<0.3, the patient was graded as 0 or 1, based on chest X-rays. Any patient on extracorporeal membrane oxygenation was Grade 3. Any subject mechanically ventilated with FiO2 greater than 0.5 or requiring nitric oxide beyond 48 hours from the time of transplant was Grade 3.

    Time frame: At ICU admission (T0), 24, 48 and 72 hours post-ICU admission

  3. Time to Freedom From Mechanical Ventilation

    Time to freedom from mechanical ventilation was defined as "time between admission to the ICU and the initial time of first extubation (breathing off mechanical ventilation without a tube) which was maintained for more than 24 hours". This number was measured in hours and was derived as (date/time of extubation-date/time of ICU admission)/3600. The longer the time, the worst the outcome.Time to freedom from mechanical ventilation, if greater than 1 month (720 hours), was censored to 720 hours. Patients re-transplanted were censored at the date/time of re-transplant. Herein differences in the time to freedom from mechanical ventilation were reported between placebo and repertaxin.

    Time frame: At 24, 48, 72 hours post ICU admission

  4. Probability of Death During Intensive Care Unit (ICU) Stay at Different Timepoints

    The duration of ICU stay, in term of hours, at different timepoints, in both placebo and repertaxin groups, was measured. The longer the ICU stay, the worse the outcome. mean event probability" (death) and its standard error (SE) at each timepoint.

    Time frame: At 24, 48, 72 hours post ICU admission

  5. Number of Patients Dead Within 30 Days Post-transplant

    Mortality, defined as any death occurring in the first 30 days post-transplant, regardless of hospital discharge.

    Time frame: Up to 30 days post-transplant

  6. Pulmonary Function Tests (FEV1=Forced Expiratory Volume in One Second and FVC=Forced Vital Capacity) at Month 1, 6 and 12 Post-transplant Evaluated According to Estenne et al.(2002).

    Forced expiratory volume in 1 second (FEV1) measured the amount/ volume, exhaled by a patient in the first second of the expiration after a full inspiration. Average values in healthy patients aged 20-60 range from 4.5 to 3.5 liters in males and from 3.25 to 2.5 liters in females. Forced vital capacity (FVC) was the volume of air that a patient could exhale with a maximal forced expiration effort after a deep inhaling, simply put, how much air a patient could breathe out by blowing as fast as possible. Average values in healthy patients aged 20-60 range from 5.5 to 4.75 liters in males and from 3.75 to 3.25 liters in females. The lower the values fo both parameters, the worse the outcome.

    Time frame: At months 1, 6 and 12 post-transplant

  7. Number of Patients With Different Bronchiolitis Obliterans Syndrome (BOS) Scores (0-3) Assessed at Months 6 and 12 Post-transplant

    BOS is defined as an irreversible decline in forced expiratory volume in 1 second (FEV1) of at least 20% from baseline. Spirometric measurements must be made with equipment that conforms to the American Thoracic Society standards for spirometric testing. Here the classification where stage 3 is the worst: BOS 0 FEV1 \>90% of baseline and FEF25-75 \>75% of baseline. BOS 0-p FEV1 \>81% to 90% of baseline and/or FEF25-75 \> 75% of baseline. BOS 1 FEV1 \>66% to 80% of baseline. BOS 2 FEV1 \>51% to 65% of baseline BOS 3 FEV1 \>50% or less of baseline. CRF data are reported.

    Time frame: At Months 6 and 12 post-transplant

  8. Number of Patients With at Least One Acute Rejection Episode at Months 1, 6 and 12 Post-transplant

    Acute rejection was diagnosed according to Yousem et al. (1996). Histopathologic assessment of transbronchial biopsies first required confirmation of the diagnosis of mild (ACR; A2) using criteria defined in the Working Formulation for Lung Allograft Rejection. Morphological variables assessed included: one or more perivascular infiltrates in the total transbronchial biopsy fragments obtained at one bronchoscopy session, the presence of large or small airway inflammation, endothelialitis, eosinophils, plasma cells, intra-airway and intra-airspace granulation tissue, and alveolar hemosiderosis. The Working Formulation for grading of acute rejection of lung allografts contains five acute rejection grades: A0, none; A1, minimal; A2, mild; A3, moderate; and A4, severe; and is based on the intensity of perivascular mononuclear infiltrates and their extension into alveolar septa.

    Time frame: At months 1, 6 and 12 post-transplant

  9. Patient Survival up to 12 Months Post-transplant

    Patient survival is derived from the date of ICU admission untile the date of death or study completion/withdrawal. Here this parameter is expressed as the "cumulative number of events (death)" at different timepoints till month 12, per arm.

    Time frame: at Months 3, 6, 9 and 12 post-transplant

  10. Number of Patients With at Least One Adverse Events Within the First Month

    An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: to month 1

  11. Number of Patients With at Least One Adverse Events From Month 1 to Month 12

    An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: from month 1 to month 12

07

Results

Posted Dec 11, 2024

Participant flow

A total of 233 subjects were screened, of whom 114 were randomised and 119 were screen failures.

Participant flow — Overall Study
MilestoneRepertaxinPlacebo
Started5559
Intention to treat population (itt)4655
Per protocol population (pp)4653
Safety population (saf)4655
Completed4652
Not completed97
Withdrew: Re-transplant02
Withdrew: Death01
Withdrew: Transplant cancelled04
Withdrew: Drug not delivered20
Withdrew: Other40
Withdrew: Transplant cancelled30

Outcome measures

PrimaryPaO2/FiO2 Ratio at ICU Admission (Time 0) and 24 Hours

The PaO2/FiO2 ratio was calculated to assess the severity of hypoxemia, or low blood oxygen levels. A low PaO2/FiO2 value has been associated with increased mortality and hospital stay in patients admitted to the intensive care unit (ICU). It was calculated by dividing the partial pressure of oxygen in arterial blood (PaO2) by the fraction of inspired oxygen (FiO2). A normal P/F ratio was typically above 300, and a lower ratio indicates a greater severity of hypoxemia. As the Pa02/Fi02 ratio was dependent on altitude, data were corrected for altitude in the analyses of corrected data. The correction factor is defined as (Pressure at Denver)/(Pressure at sea level) = 633/760 = 0.8329; PaO2 values were corrected as follows: Corrected value = measured value/0.8329

Time frame:
At T0 (time of ICU admission) and 24 hours post-ICU admission
Reported as:
Mean · ratio of PaO2/FiO2
PaO2/FiO2 Ratio at ICU Admission (Time 0) and 24 Hours
ratio of PaO2/FiO2Repertaxin (ITT)Placebo (ITT)
ICU Admission (Time 0)346.3 ± 125.5337.9 ± 143.0
24 Hours Post ICU Admission320.1 ± 119.5307.3 ± 111.3
Statistical analysis
  • Repertaxin (ITT) vs Placebo (ITT) · t-test, 1 sided · p = 0.8541 · Mean difference (final values): 5.022
  • Repertaxin (ITT) vs Placebo (ITT) · t-test, 1 sided · p = 0.6996 · Mean difference (final values): 10.426
SecondaryPaO2/FiO2 Ratio (ICU Admission Then 24 Hours up to Extubation or up to 72 Hours)

Time profile of oxygenation was a comparison of the sequential measurements of the ratios of arterial PaO2 to inspired oxygen fractions FiO2. Herein repeated measurements analysis of PaO2/FiO2 ratio corrected after ICU admission using a one-sided test excluding missing data.

Time frame:
At ICU admission (T0), 24, 48 and 72 hours post-ICU admission
Reported as:
Mean · ratio of PaO2/FiO2
PaO2/FiO2 Ratio (ICU Admission Then 24 Hours up to Extubation or up to 72 Hours)
ratio of PaO2/FiO2Repertaxin (ITT)Placebo (ITT)
ICU Admission (Time 0)346.3 ± 125.5337.9 ± 143.0
24 Hours Post ICU Admission320.1 ± 119.5307.3 ± 111.3
48 Hours Post ICU Admission266.1 ± 117.3279.2 ± 151.8
72 Hours Post ICU Admission275.6 ± 88.1233.9 ± 132.0
Statistical analysis
  • Repertaxin (ITT) vs Placebo (ITT) · t-test, 1 sided · p = 0.8654 · Mean difference (final values): 4.377
  • Repertaxin (ITT) vs Placebo (ITT) · t-test, 1 sided · p = 0.6789 · Median difference (final values): 13.386
  • Repertaxin (ITT) vs Placebo (ITT) · t-test, 1 sided · p = 0.6345 · Mean difference (final values): -19.968
  • Repertaxin (ITT) vs Placebo (ITT) · t-test, 1 sided · p = 0.9858 · Mean difference (final values): 0.908
SecondaryNumber of Patients With Different Primary Graft Dysfunction (PGD) Scores (0-3, and Missing Data)

PGD after lung transplantation ranged from mild to severe depending on the level of hypoxaemia and lung injury post-transplant. PGD score was calculated according to the scoring system below: Grade 0 PaO2/FiO2 \>=300 mmHg; no radiographic infiltrates (RI); Grade 1 PaO2/FiO2 \>=300mmHg + RI consistent with pulmonary oedema; Grade 2 200 mmHg \<=PaO2/FiO2 \<=300 mm Hg + RI consistent with pulmonary oedema; Grade 3 PaO2/FiO2 \< 200 mm Hg + RI consistent with pulmonary oedema. The higher the score, the worse the outcome. Any patient with no infiltrate on chest X-rays was automatically Grade 0. If the patient was on nasal cannula for oxygen or FiO2 \<0.3, the patient was graded as 0 or 1, based on chest X-rays. Any patient on extracorporeal membrane oxygenation was Grade 3. Any subject mechanically ventilated with FiO2 greater than 0.5 or requiring nitric oxide beyond 48 hours from the time of transplant was Grade 3.

Time frame:
At ICU admission (T0), 24, 48 and 72 hours post-ICU admission
Reported as:
Count of participants · Participants
Number of Patients With Different Primary Graft Dysfunction (PGD) Scores (0-3, and Missing Data)
ParticipantsRepertaxin (ITT)Placebo (ITT)
ICU Admission (Time 0) - PGD Score Missing01
ICU Admission (Time 0) - PGD Score 02833
ICU Admission (Time 0) - PGD Score 198
ICU Admission (Time 0) - PGD Score 264
ICU Admission (Time 0) - PGD Score 339
24 Hours Post ICU Admission - PGD Score Missing01
24 Hours Post ICU Admission - PGD Score 02230
24 Hours Post ICU Admission - PGD Score 11412
24 Hours Post ICU Admission - PGD Score 256
24 Hours Post ICU Admission - PGD Score 356
48 Hours Post ICU Admission - PGD Score Missing03
48 Hours Post ICU Admission - PGD Score 02224
48 Hours Post ICU Admission - PGD Score 11517
48 Hours Post ICU Admission - PGD Score 242
48 Hours Post ICU Admission - PGD Score 359
72 Hours Post ICU Admission - PGD Score Missing13
72 Hours Post ICU Admission - PGD Score 02227
72 Hours Post ICU Admission - PGD Score 11617
72 Hours Post ICU Admission - PGD Score 232
72 Hours Post ICU Admission - PGD Score 346
Statistical analysis
  • Repertaxin (ITT) vs Placebo (ITT) · Cochran-Mantel-Haenszel · p = 0.7985 · Odds ratio (or): 2.867 · 95% CI 0.727 to 11.302Odds ratio is Repertaxin:Placebo ratio of PGD scores 0-2:PGD score 3 odds
  • Repertaxin (ITT) vs Placebo (ITT) · Cochran-Mantel-Haenszel · p = 0.5606 · Odds ratio (or): 0.837 · 95% CI 0.226 to 3.092Odds ratio is Repertaxin:Placebo ratio of PGD scores 0-2:PGD score 3 odds
  • Repertaxin (ITT) vs Placebo (ITT) · Cochran-Mantel-Haenszel · p = 0.8786 · Odds ratio (or): 1.716 · 95% CI 0.531 to 5.552Odds ratio is Repertaxin:Placebo ratio of PGD scores 0-2:PGD score 3 odds
  • Repertaxin (ITT) vs Placebo (ITT) · Cochran-Mantel-Haenszel · p = 0.8499 · Odds ratio (or): 1.337 · 95% CI 0.352 to 5.072Odds ratio is Repertaxin:Placebo ratio of PGD scores 0-2:PGD score 3 odds
SecondaryTime to Freedom From Mechanical Ventilation

Time to freedom from mechanical ventilation was defined as "time between admission to the ICU and the initial time of first extubation (breathing off mechanical ventilation without a tube) which was maintained for more than 24 hours". This number was measured in hours and was derived as (date/time of extubation-date/time of ICU admission)/3600. The longer the time, the worst the outcome.Time to freedom from mechanical ventilation, if greater than 1 month (720 hours), was censored to 720 hours. Patients re-transplanted were censored at the date/time of re-transplant. Herein differences in the time to freedom from mechanical ventilation were reported between placebo and repertaxin.

Time frame:
At 24, 48, 72 hours post ICU admission
Reported as:
Mean · hours
Time to Freedom From Mechanical Ventilation
hoursRepertaxin (ITT)Placebo (ITT)
24 Hours Post-ICU Admission0.5000 ± 0.07370.4909 ± 0.0674
48 Hours Post-ICU Admission0.6957 ± 0.06780.7273 ± 0.0601
72 Hours Post-ICU Admission0.7391 ± 0.06470.8052 ± 0.0541
Statistical analysis
  • Repertaxin (ITT) vs Placebo (ITT) · Log Rank · p = 0.7076 · Difference in event probability: 0.0091 · 95% CI -0.1867 to 0.2049
  • Repertaxin (ITT) vs Placebo (ITT) · Log Rank · p = 0.7076 · Difference in event probability: -0.0316 · 95% CI -0.2092 to 0.1460
  • Repertaxin (ITT) vs Placebo (ITT) · Log Rank · p = 0.7076 · Difference in event probability: -0.0661 · 95% CI -0.2314 to 0.0993
SecondaryProbability of Death During Intensive Care Unit (ICU) Stay at Different Timepoints

The duration of ICU stay, in term of hours, at different timepoints, in both placebo and repertaxin groups, was measured. The longer the ICU stay, the worse the outcome. mean event probability" (death) and its standard error (SE) at each timepoint.

Time frame:
At 24, 48, 72 hours post ICU admission
Reported as:
Mean · event probability
Probability of Death During Intensive Care Unit (ICU) Stay at Different Timepoints
event probabilityRepertaxin (ITT)Placebo (ITT)
At 24 h hours post ICU admission0.0000 ± 0.00000.0364 ± 0.0252
At 48 h hours post ICU admission0.3261 ± 0.06910.2909 ± 0.0612
At 72 h hours post ICU admission0.4783 ± 0.07370.4962 ± 0.0679
Statistical analysis
  • Repertaxin (ITT) vs Placebo (ITT) · Log Rank · p = 0.9632 · Difference in event probability: -0.0364 · 95% CI -0.0858 to 0.0131
  • Repertaxin (ITT) vs Placebo (ITT) · Log Rank · p = 0.9632 · Difference in event probability: 0.0352 · 95% CI -0.1458 to 0.2162
  • Repertaxin (ITT) vs Placebo (ITT) · Log Rank · p = 0.9632 · Difference in event probability: -0.0179 · 95% CI -0.2143 to 0.1785
SecondaryNumber of Patients Dead Within 30 Days Post-transplant

Mortality, defined as any death occurring in the first 30 days post-transplant, regardless of hospital discharge.

Time frame:
Up to 30 days post-transplant
Reported as:
Count of participants · Participants
Number of Patients Dead Within 30 Days Post-transplant
ParticipantsRepertaxin (ITT)Placebo (ITT)
Number of Patients Dead Within 30 Days Post-transplant01
SecondaryPulmonary Function Tests (FEV1=Forced Expiratory Volume in One Second and FVC=Forced Vital Capacity) at Month 1, 6 and 12 Post-transplant Evaluated According to Estenne et al.(2002).

Forced expiratory volume in 1 second (FEV1) measured the amount/ volume, exhaled by a patient in the first second of the expiration after a full inspiration. Average values in healthy patients aged 20-60 range from 4.5 to 3.5 liters in males and from 3.25 to 2.5 liters in females. Forced vital capacity (FVC) was the volume of air that a patient could exhale with a maximal forced expiration effort after a deep inhaling, simply put, how much air a patient could breathe out by blowing as fast as possible. Average values in healthy patients aged 20-60 range from 5.5 to 4.75 liters in males and from 3.75 to 3.25 liters in females. The lower the values fo both parameters, the worse the outcome.

Time frame:
At months 1, 6 and 12 post-transplant
Reported as:
Mean · Litres
Pulmonary Function Tests (FEV1=Forced Expiratory Volume in One Second and FVC=Forced Vital Capacity) at Month 1, 6 and 12 Post-transplant Evaluated According to Estenne et al.(2002).
LitresRepertaxin (ITT)Placebo (ITT)
FEV1 - Month 1 post transplant2.20 ± 0.742.05 ± 0.84
FEV1 - Month 6 post transplant2.62 ± 0.952.34 ± 0.85
FEV1 - Month 12 post transplant2.52 ± 1.072.22 ± 0.95
FVC - Month 1 post transplant2.49 ± 0.702.56 ± 1.01
FVC - Month 6 post transplant3.19 ± 0.933.11 ± 0.99
FVC - Month 12 post transplant3.19 ± 1.053.07 ± 1.10
SecondaryNumber of Patients With Different Bronchiolitis Obliterans Syndrome (BOS) Scores (0-3) Assessed at Months 6 and 12 Post-transplant

BOS is defined as an irreversible decline in forced expiratory volume in 1 second (FEV1) of at least 20% from baseline. Spirometric measurements must be made with equipment that conforms to the American Thoracic Society standards for spirometric testing. Here the classification where stage 3 is the worst: BOS 0 FEV1 \>90% of baseline and FEF25-75 \>75% of baseline. BOS 0-p FEV1 \>81% to 90% of baseline and/or FEF25-75 \> 75% of baseline. BOS 1 FEV1 \>66% to 80% of baseline. BOS 2 FEV1 \>51% to 65% of baseline BOS 3 FEV1 \>50% or less of baseline. CRF data are reported.

Time frame:
At Months 6 and 12 post-transplant
Reported as:
Count of participants · Participants
Number of Patients With Different Bronchiolitis Obliterans Syndrome (BOS) Scores (0-3) Assessed at Months 6 and 12 Post-transplant
ParticipantsRepertaxin (ITT)Placebo (ITT)
Month 6 Post Transplant - BOS Missing04
Month 6 Post Transplant - BOS 04544
Month 6 Post Transplant - BOS 113
Month 6 Post Transplant - BOS 201
Month 6 Post Transplant - BOS 300
Month 12 Post Transplant - Missing47
Month 12 Post Transplant - BOS 03536
Month 12 Post Transplant - BOS 115
Month 12 Post Transplant - BOS 232
Month 12 Post Transplant - BOS 332
SecondaryNumber of Patients With at Least One Acute Rejection Episode at Months 1, 6 and 12 Post-transplant

Acute rejection was diagnosed according to Yousem et al. (1996). Histopathologic assessment of transbronchial biopsies first required confirmation of the diagnosis of mild (ACR; A2) using criteria defined in the Working Formulation for Lung Allograft Rejection. Morphological variables assessed included: one or more perivascular infiltrates in the total transbronchial biopsy fragments obtained at one bronchoscopy session, the presence of large or small airway inflammation, endothelialitis, eosinophils, plasma cells, intra-airway and intra-airspace granulation tissue, and alveolar hemosiderosis. The Working Formulation for grading of acute rejection of lung allografts contains five acute rejection grades: A0, none; A1, minimal; A2, mild; A3, moderate; and A4, severe; and is based on the intensity of perivascular mononuclear infiltrates and their extension into alveolar septa.

Time frame:
At months 1, 6 and 12 post-transplant
Reported as:
Count of participants · Participants
Number of Patients With at Least One Acute Rejection Episode at Months 1, 6 and 12 Post-transplant
ParticipantsRepertaxin (ITT)Placebo (ITT)
Month 1 Post transplant1719
Month 6 Post Transplant3533
Month 12 Post Transplant1713
SecondaryPatient Survival up to 12 Months Post-transplant

Patient survival is derived from the date of ICU admission untile the date of death or study completion/withdrawal. Here this parameter is expressed as the "cumulative number of events (death)" at different timepoints till month 12, per arm.

Time frame:
at Months 3, 6, 9 and 12 post-transplant
Reported as:
Number · number of events
Patient Survival up to 12 Months Post-transplant
number of eventsRepertaxin (ITT)Placebo (ITT)
3 Months03
6 Months05
9 Months06
12 Months07
Statistical analysis
  • Repertaxin (ITT) vs Placebo (ITT) · Log Rank · p = 0.0111 · Difference in event probability: -0.0566 · 95% CI -0.1188 to 0.0056
  • Repertaxin (ITT) vs Placebo (ITT) · Log Rank · p = 0.0111 · Difference in event probability: -0.0943 · 95% CI -0.1730 to -0.0156
  • Repertaxin (ITT) vs Placebo (ITT) · Log Rank · p = 0.0111 · Difference in event probability: -0.1132 · 95% CI -0.1985 to -0.0279
  • Repertaxin (ITT) vs Placebo (ITT) · Log Rank · p = 0.0111 · Slope: -0.1334 · 95% CI -0.2254 to -0.0413
SecondaryNumber of Patients With at Least One Adverse Events Within the First Month

An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Time frame:
to month 1
Reported as:
Count of participants · Participants
Number of Patients With at Least One Adverse Events Within the First Month
ParticipantsRepertaxin (SAF)Placebo (SAF)
Number (%) of patients reporting at least one TEAE4655
Number (%) of patients reporting at least one TEAE leading to discontinuation of study drug10
Number (%) of patients reporting at least one serious TEAE1414
Number (%) of patients reporting at least one TEAE leading to death00
Number (%) of patients reporting TEAEs with no relationship to study drug1926
Number (%) of patients reporting TEAEs with unlikely relationship to study drug1822
Number (%) of patients reporting TEAEs with possible study drug97
Number (%) of patients reporting TEAEs with probable relationship to study drug00
Number (%) of patients reporting TEAEs with highly probable relationship to study drug00
Number (%) of patients reporting Serious TEAEs with no relationship to study drug56
Number (%) of patients reporting Serious TEAEs with unlikely relationship to study drug56
Number (%) of patients reporting Serious TEAEs with possible relationship to study drug42
Number (%) of patients reporting Serious TEAEs with probable relationship to study drug00
Number (%) of patients reporting Serious TEAEs with highly probable relationship to study drug00
SecondaryNumber of Patients With at Least One Adverse Events From Month 1 to Month 12

An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Time frame:
from month 1 to month 12
Reported as:
Number · participants
Number of Patients With at Least One Adverse Events From Month 1 to Month 12
participantsRepertaxin (SAF)Placebo (SAF)
Number of patients with TEAEs4640
Number (%) of patients reporting at least one TEAE2120
Number (%) of patients reporting at least one TEAE leading to discontinuation of study drug00
Number (%) of patients reporting at least one serious TEAE00
Number (%) of patients reporting at least one TEAE leading to death00
Number (%) of patients reporting TEAEs with no relationship to study drug119
Number (%) of patients reporting TEAEs with unlikely relationship to study drug98
Number (%) of patients reporting TEAEs with possible relationship to study drug13
Number (%) of patients reporting TEAEs with probable relationship to study drug00
Number (%) of patients reporting TEAEs with highly probable relationship to study drug00

Adverse events

Collected over The specific period of time over which adverse events data were collected was from the start of infusion to Month 12 visit. Note that in Placebo population the number of subject was 52 instead of 55 in the period from Month 1 to Month 12.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Repertaxin (SAF)1/46 (2.2%)14/46 (30.4%)46/46 (100%)
Placebo (SAF)6/55 (10.9%)14/55 (25.5%)55/55 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventRepertaxin (SAF)Placebo (SAF)
CoagulopathyBlood and lymphatic system disorders3/462/55
PneumothoraxRespiratory, thoracic and mediastinal disorders3/460/55
Atrial fibrillationCardiac disorders1/463/55
HaemorrageVascular disorders2/463/55
HypotensionVascular disorders0/463/55
Lung transplant rejectionImmune system disorders1/462/55
Respiratory failureRespiratory, thoracic and mediastinal disorders1/462/55
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/462/55
Reperfusion injuryVascular disorders0/462/55
Cardiac arrestCardiac disorders1/460/55
Most frequent other events
Showing 10 of 204
Most frequent other events
EventRepertaxin (SAF)Placebo (SAF)
Incision site complicationInjury, poisoning and procedural complications35/4633/55
ConstipationGastrointestinal disorders28/4621/55
NauseaGastrointestinal disorders20/4619/55
HyperglycaemiaMetabolism and nutrition disorders20/4623/55
HypotensionVascular disorders14/4614/55
HypomagnesaemiaMetabolism and nutrition disorders12/4616/55
AnaemiaBlood and lymphatic system disorders13/465/55
HypokalaemiaMetabolism and nutrition disorders12/4615/55
HypervolaemiaMetabolism and nutrition disorders5/4614/55
InsomniaPsychiatric disorders11/4613/55

Baseline characteristics

The safety population (SAF) consisted of all patients who received any study medication and was based on the treatment actually received.

Age, Categorical
Age, Categorical(Participants)Repertaxin (SAF)Placebo (SAF)Total
<=18 years011
Between 18 and 65 years465096
>=65 years044
Age, Continuous
Age, Continuous(years)Repertaxin (SAF)Placebo (SAF)Total
Mean46.2 ± 13.550.9 ± 12.248.7 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)Repertaxin (SAF)Placebo (SAF)Total
Female232750
Male232851
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Repertaxin (SAF)Placebo (SAF)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White4555100
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Repertaxin (SAF)Placebo (SAF)Total
Canada161733
United States303868
08

Study locations

6 sites
  • University of South California, Department of Cardiothoracic Surgery
    Los Angeles, California 90033, United States
  • University of Colorado, Health Sciences Centre
    Denver, Colorado 80262, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Toronto General Hospital
    Toronto, Ontario M5G2C4, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2005 to primary completion in Sep 2006, 16 months.

Results were first posted in Dec 2024, 18 years 2 months after primary completion.

Of 18 phase 2 interventional studies under Reperfusion Injury, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2005
First posted
Sep 23, 2005
StartActual
May 1, 2005
Primary completionActual
Sep 13, 2006
CompletionActual
Sep 13, 2007
Results first posted
Dec 11, 2024
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00224406
Responsible party
Sponsor
First posted
Sep 23, 2005
Start date
May 1, 2005
Primary completion
Sep 13, 2006
Completion
Sep 13, 2007
Results posted
Dec 11, 2024
Last update
Dec 11, 2024

Study contacts

Roberto Novellini, MD
study director · Dompé Farmaceutici S.p.A

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Reparixin

Start the discussion